Evaluating the effectiveness and safety of Dalbavancin for infection treatment
Efficacy and Safety of Dalbavancin As Suppressive Therapy
Hospices Civils de Lyon · NCT06899906
This study is testing if Dalbavancin, a long-lasting antibiotic, is safe and effective for people who have been on other antibiotics for their infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 33 (estimated) |
| Sex | All |
| Sponsor | Hospices Civils de Lyon (other) |
| Locations | 1 site (France, Lyon) |
| Trial ID | NCT06899906 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the efficacy and safety of Dalbavancin, a semi-synthetic antibiotic, in patients who have received suppressive antibiotic therapy (SAT) for acute or chronic infections. The study focuses on patients treated between July 2019 and December 2024, gathering demographic and clinical characteristics at baseline. Dalbavancin is known for its long half-life and ability to penetrate various tissues, making it a promising option for treating Gram-positive infections.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 who have received Dalbavancin as part of their treatment for acute or chronic infections.
Not a fit: Patients under 18 years old or those who received Dalbavancin for purposes other than SAT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the effectiveness of Dalbavancin as a long-term treatment option for patients with difficult-to-treat infections.
How similar studies have performed: While there have been studies on Dalbavancin, this specific observational approach focusing on SAT is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> 18 years * Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024 * Patient who was informed and did not object to participating in the study Exclusion Criteria: * -\< 18 years * Subjects who received DAL not for SAT purposes
Where this trial is running
France, Lyon
- HCL — France, Lyon, France (RECRUITING)
Study contacts
- Study coordinator: Tristan Ferry
- Email: Tristan.ferry@chu-lyon.fr
- Phone: + 33 4 72 07 24 81
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Efficacy and Safety of Dalbavancin, In Subjects Who Received SAT with DAL, For Acute or Chronic Infections Between July 2019 and December 2024